Suppr超能文献

腹膜透析患者发生肠源性微生物所致腹膜炎的危险因素。

Risk factors for developing peritonitis caused by micro-organisms of enteral origin in peritoneal dialysis patients.

作者信息

Caravaca F, Ruiz-Calero R, Dominguez C

机构信息

Service of Nephrology, Regional Hospital University Infanta Cristina, Badajoz, Spain.

出版信息

Perit Dial Int. 1998 Jan-Feb;18(1):41-5.

PMID:9527028
Abstract

OBJECTIVE

To investigate the risk factors associated with the development of peritonitis caused by enteral bacteria in peritoneal dialysis patients, including the prescription of gastric acid inhibitors as a potential risk factor.

DESIGN

Retrospective single-center study.

SETTING

Tertiary university hospital.

PATIENTS AND MAIN OUTCOME MEASURES

Fifty-five patients who entered into our continuous ambulatory peritoneal dialysis (CAPD) program during the last 6 years were included. Multiple logistic regression analysis was used to establish the best determinants over the development of at least one episode of enteric peritonitis. The predictive variables included in the model were: age, gender, diabetic versus nondiabetic, polycystic versus nonpolycystic kidney diseases, history of constipation, presence or absence of moderate/severe malnutrition, peritoneal transport characteristics, peritoneal protein losses, rate of exit-site infections, rate of total peritonitis, intestinal abnormalities, and treatment with inhibitors of gastric acid secretion.

RESULTS

The total number of peritonitis episodes during the studied period was 88, which clustered in 34 of 55 patients. Fourteen (16%) were caused by enteric micro-organisms in 10 patients: Escherichia coli (6), Klebsiella sp (2), Enterobacter sp (1), and Enterococcus sp (5). Nine of 10 patients who developed enteric peritonitis were on gastric acid inhibitors (3 patients on omeprazole and 6 patients on H2-antagonists), while 15 of 45 patients who did not develop enteric peritonitis were on gastric acid inhibitors (all of them on H2-blockers). There were temporal relationships between the start of gastric acid inhibitors and the development of enteric peritonitis in 6 of 9 patients who were on this medication. Four of 10 patients who developed enteric peritonitis had diverticulosis. Ten of 45 patients who did not develop enteric peritonitis had been diagnosed with diverticulosis of the colon or sigmoid prior to entry to CAPD. The unique patient who was not on gastric acid inhibitors and developed enteric peritonitis, had been diagnosed with chronic atrophic gastritis with achlorhydria. By multiple logistic regression analysis, the treatment with gastric acid inhibitors was the only independent variable that entered into the best predictive equation over the development of enteric peritonitis (log likelihood ratio = -26.077, odds ratio = 18; 95% CI odds ratio: 2 - 155).

CONCLUSION

Gastric acid inhibitors may increase the risk for developing enteric peritonitis in peritoneal dialysis patients.

摘要

目的

探讨腹膜透析患者肠源性细菌所致腹膜炎发生的相关危险因素,包括将胃酸抑制剂的使用作为潜在危险因素进行研究。

设计

回顾性单中心研究。

地点

三级大学医院。

患者及主要观察指标

纳入过去6年进入我院持续性非卧床腹膜透析(CAPD)项目的55例患者。采用多因素logistic回归分析确定至少发生1次肠道腹膜炎的最佳决定因素。模型中纳入的预测变量包括:年龄、性别、糖尿病与非糖尿病、多囊肾病与非多囊肾病、便秘史、是否存在中度/重度营养不良、腹膜转运特性、腹膜蛋白丢失、出口处感染率、总腹膜炎发生率、肠道异常情况以及胃酸分泌抑制剂治疗情况。

结果

研究期间腹膜炎发作总数为88次,55例患者中有34例发生。10例患者中有14次(16%)由肠道微生物引起:大肠杆菌(6次)、克雷伯菌属(2次)、肠杆菌属(1次)和肠球菌属(5次)。发生肠道腹膜炎的10例患者中有9例正在使用胃酸抑制剂(3例使用奥美拉唑,6例使用H2拮抗剂),而未发生肠道腹膜炎的45例患者中有15例正在使用胃酸抑制剂(均使用H2阻滞剂)。在使用该药物的9例患者中,有6例胃酸抑制剂的使用与肠道腹膜炎的发生存在时间关系。发生肠道腹膜炎的10例患者中有4例患有憩室病。未发生肠道腹膜炎的45例患者中有10例在进入CAPD之前被诊断为结肠或乙状结肠憩室病。唯一未使用胃酸抑制剂却发生肠道腹膜炎的患者被诊断为慢性萎缩性胃炎伴无酸症。通过多因素logistic回归分析表明,使用胃酸抑制剂治疗是肠道腹膜炎发生的最佳预测方程中唯一进入的独立变量(对数似然比=-26.077,比值比=18;95%CI比值比:2-155)。

结论

胃酸抑制剂可能增加腹膜透析患者发生肠道腹膜炎的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验